Abstract
Adenohypophyseal tumors, which were recently renamed pituitary neuroendocrine tumors (PitNET), are mostly benign, but may present various behaviors: invasive, “aggressive” and malignant with metastases. They are classified into seven morphofunctional types and three lineages: lactotroph, somatotroph and thyrotroph (PIT1 lineage), corticotroph (TPIT lineage) or gonadotroph (SF1 lineage), null cell or immunonegative tumor and plurihormonal tumors. The WHO 2017 classification suggested that subtypes, such as male lactotroph, silent corticotroph and Crooke cell, sparsely granulated somatotroph, and silent plurihormonal PIT1 positive tumors, should be considered as “high risk” tumors. However, the prognostic impact of these subtypes and of each morphologic type remains controversial. In contrast, the French five-tiered classification, taking into account the invasion, the immuno-histochemical (IHC) type, and the proliferative markers (Ki-67 index, mitotic count, p53 positivity), has a prognostic value validated by statistical analysis in 4 independent cohorts. A standardized report for the diagnosis of pituitary tumors, integrating all these parameters, has been proposed by the European Pituitary Pathology Group (EPPG). In 2020, the pituitary pathologist must be considered as a member of the multidisciplinary pituitary team. The pathological diagnosis may help the clinician to adapt the post-operative management, including appropriate follow-up and early recognition and treatment of potentially aggressive forms.
Highlights
For about a century, acromegaly and Cushing’s disease have been considered endocrine conditions of hypothalamic origin or due to a benign pituitary tumor named “adenoma”
A large majority of pituitary neuroendocrine tumors (PitNET) will behave as well differentiated, benign neoplasms, we believe that this terminology can only impact positively on clinical practice as it reflects more closely the variability of behavior of pituitary tumor and may open up new strategies for the early identification and management of the most aggressive forms
The World HealthOrganization (WHO) classification published in 2004 [33] classified tumors into seven main types: growth hormone (GH), PRL, FSH/LH, ACTH, and TSH-producing lesions based on their immunoprofile (IHC for pituitary hormones), subdivided into 13 ultrastructural subtypes
Summary
Acromegaly and Cushing’s disease have been considered endocrine conditions of hypothalamic origin or due to a benign pituitary tumor named “adenoma”. In 2017, the members of the International Pituitary Pathology Club proposed the use of the term “neuroendocrine tumor” rather than “adenoma” to define tumors of adenohypophyseal cells [4]. A large majority of PitNETs will behave as well differentiated, benign neoplasms, we believe that this terminology can only impact positively on clinical practice as it reflects more closely the variability of behavior of pituitary tumor (invasiveness linked to a higher risk of recurrence) and may open up new strategies for the early identification and management of the most aggressive forms. It is proven that the anxiety of patients, when exposed to new terminologies, can be dealt with by experienced physicians [7] For such reasons, we have chosen to endorse the terminology of PitNET
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
